1202388-64-4
Chemical Structure
IAXO-101 iodide
- CAS No.: 1202388-64-4
- Formula:C42H84INO5
- Molecular Weight:810.02
IUPAC Name: N-(((2R,3R,4S,5R,6S)-3-hydroxy-6-methoxy-4,5-bis(tetradecyloxy)tetrahydro-2H-pyran-2-yl)methyl)-N,N-dimethylcyclopentanaminium iodide
InChIKey: BEFLBKFGGQBVHS-MDMJKWFXSA-M
SMILES: CCCCCCCCCCCCCCO[C@@H]1[C@H]([C@@H]([C@@H](C[N+](C)(C2CCCC2)C)O[C@@H]1OC)O)OCCCCCCCCCCCCCC.[I-]
Biological Activity: IAXO-101 iodide is a TLR4/CD14 blocker. IAXO-101 iodide can inhibit the innate immune pathway of CD14. IAXO-101 iodide is capable of improving the recording performance of intracortical microelectrodes in mice. IAXO-101 iodide can also partially alleviate fetal growth restriction, placental vascular damage, and reduce the level of the inflammatory factor TNF-α in pregnant mice infected with malaria. IAXO-101 iodide can be used in the research of gestational malaria and inflammatory diseases[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
IAXO-101 iodide | IAXO-101 iodide is a TLR4/CD14 blocker. IAXO-101 iodide can inhibit the innate immune pathway of CD14. IAXO-101 iodide is capable of improving the recording performance of intracortical microelectrodes in mice. IAXO-101 iodide can also partially alleviate fetal growth restriction, placental vascular damage, and reduce the level of the inflammatory factor TNF-α in pregnant mice infected with malaria. IAXO-101 iodide can be used in the research of gestational malaria and inflammatory diseases. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Hermann JK, et al. Inhibition of the cluster of differentiation 14 innate immunity pathway with IAXO-101 improves chronic microelectrode performance. J Neural Eng. 2018 Apr;15(2):025002. [Content Brief]
- [2]. Barboza R, et al. TLR4-Mediated Placental Pathology and Pregnancy Outcome in Experimental Malaria. Sci Rep. 2017 Aug 17;7(1):8623. [Content Brief]
